IFALPA: Global Pilots on Pakistan International Airlines Flight PK-8303

Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday. First Vascepa Generic Greenlighted The negative sentiment is attributable to another announcement by U.K.-based generic manufacturer Hikma Biologics that its U.S. subsidiary Hikma Pharmaceuticals USA has received FDA approval for a generic version of Amarin's Vascepa. This makes Hikma the first to receive approval for an abbreviated new drug application for a generic version of Vascepa. Indian generic manufacturer Dr.Reddy's Laboratories Ltd (NYSE: RDY) has also filed an ANDA with the FDA for Vascepa.Why A Vascepa Generic Launch Many Not Be Imminent Despite the generic approval, Hikma is unlikely to launch at-risk, SVB Leerink analyst Ami Fadia said in a Friday note. An at-risk generic launch occurs when a company introduces a generic drug even as litigation contesting...

3 Stocks to Buy After the Headline Panic

It's all about the news for many on Wall Street. But headlines are also prone to fading away or even revision, as we've seen this week. It literally can be "yesterday's news" in a jiffy. And opportunistic investors can occasionally turn to the price chart and use others' distress from the latest news report to find excellent stocks to buy cheap. Let me explain.In Friday's first half of trade, the headlines are insisting it's all about escalating tensions between the world's two largest super powers. But that's not exactly new news, is it? We've seen this type of political theater before. And on each of those countless headline warnings, as others were fearfully selling, investors purchasing the panic were rewarded. * 7 Inexpensive, High-Dividend ETFs to Buy Still, the fact is, extracting profits from headlines or timing entries and exits based on the latest news is tricky business. This week's bullish...